Phase II study of axitinib intensification compared to nivolumab alone after induction with ipilimumab plus nivolumab in patients with mRCC without previous complete response (AxIn study).

被引：0

作者：

Ciccarese, Chiara

Verzoni, Elena

Bimbatti, Davide

Buti, Sebastiano

Calabro, Fabio

Galli, Luca

Scagliarini, Sarah

Fornarini, Giuseppe

Baldessari, Cinzia

Bilancia, Domenico

Facchini, Gaetano

Cattrini, Carlo

Masini, Cristina

Giganti, Maria Olga

Scandurra, Giuseppa

Nole, Franco

Berruti, Alfredo

Milella, Michele

Antonuzzo, Lorenzo

Iacovelli, Roberto

机构：

[1] Univ Cattolica Sacro Cuore, Fdn Policlin Univ A Gemelli IRCCS, Oncol Unit, Rome, Italy

[2] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy

[3] IOV IRCCS, Ist Oncol Veneto, Oncol Unit 1, Padua, Italy

[4] Univ Hosp Parma, Fontevivo, Italy

[5] IFO Ist Regina Elena, Rome, Italy

[6] Univ Pisana, UO Oncol Med 2 Univ Azienda Osped, Pisa, Italy

[7] Cardarelli Hosp, Dept Oncol, Naples, Italy

[8] IRCCS Osped Policlin San Martino, Genoa, Italy

[9] Azienda Osped Univ Policlin Modena, Oncol Unit, Modena, Italy

[10] Azienda Osped S Carlo, Potenza, Italy

[11] SM delle Grazie Hosp, Med Oncol Unit, Pozzuoli, Italy

[12] Azienda Osped Maggiore Carita, Novara, Italy

[13] AUSL IRCCS Reggio Emilia, Reggio Emilia, Italy

[14] Osped Cremona, Cremona, Italy

[15] Humanitas Ctr Catanese Oncol, Catania, Italy

[16] IRCCS Ist Europeo Oncol, Milan, Italy

[17] Univ Brescia, Dept Med & Surg Special Radiol Sci & Publ Hlth, Med Oncol Unit, ASST Spedali Civili, Brescia, Italy

[18] Univ Verona, Sch Med, Sect Oncol, Verona, Italy

[19] Verona Univ Hosp Trust, Verona, Italy

[20] Sodc Ematol Azienda Osped Careggi, Florence, Italy

[21] Fdn Policlin Univ A Gemelli, IRCCS, Rome, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期

关键词：

283-2494-9200; 261-492-3532-2370-7650-2700; 261-492-11294; 261-492-3532-2370; 261-492-3532-2373; 261-492-5651-9270-5652; 261-492-5651-9270-5657; 4; 3; 2; 14; 319; 3581; 137; 3585; 8; 1;

D O I：

10.1200/JCO.2024.42.4_suppl.TPS494

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：TPS494 / TPS494

页数：1

共 50 条

[41] Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden
Schenker, Michael
Burotto, Mauricio
Richardet, Martin
Ciuleanu, Tudor-Eliade
Goncalves, Anthony
Steeghs, Neeltje
Schoffski, Patrick
Ascierto, Paolo A.
Maio, Michele
Lugowska, Iwona
Lupinacci, Lorena
Leary, Alexandra
Delord, Jean-Pierre
Grasselli, Julieta
Tan, David S. P.
Friedmann, Jennifer
Vuky, Jacqueline
Tschaika, Marina
Konduru, Somasekhar
Vemula, Sai Vikram
Slepetis, Ruta
Kollia, Georgia
Pacius, Misena
Duong, Quyen
Huang, Ning
Doshi, Parul
Baden, Jonathan
Di Nicola, Massimo
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (08) : 1 - 11
[42] Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC)
Chen, Inna M.
Johansen, Julia S.
Theile, Susann
Hjaltelin, Jessica X.
Novitski, Sif, I
Brunak, Soren
Hasselby, Jane P.
Willemoe, Gro L.
Lorentzen, Torben
Madsen, Kasper
Jensen, Benny, V
Wilken, Eva E.
Geertsen, Poul
Behrens, Claus
Nolsoe, Christian
Hermann, Kirstine L.
Svane, Inge Marie
Nielsen, Dorte
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (27) : 3180 - +
[43] Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204.
Tawbi, Hussein Abdul-Hassan
Forsyth, Peter A. J.
Algazi, Alain Patrick
Hamid, Omid
Hodi, F. Stephen
Moschos, Stergios J.
Khushalani, Nikhil I.
Gonzalez, Rene
Lao, Christopher D.
Postow, Michael Andrew
Atkins, Michael B.
Ernstoff, Marc S.
Puzanov, Igor
Kudchadkar, Ragini Reiney
Thomas, Reena Parada
Tarhini, Ahmad A.
Jiang, Joel
Avila, Alexandre
Demelo, Sheena
Margolin, Kim Allyson
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[44] Prospective Phase I/II Study of Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable NSCLC
Liveringhouse, C.
Lam, N. B.
Rosenberg, S. A.
Dilling, T. J.
Macmillan, G.
Chiappori, A.
Haura, E. B.
Creelan, B.
Gray, J.
Tanvetyanon, T.
Shafique, M.
Saltos, A. N.
Weiner, A. A.
Kelsey, C. R.
Schell, M.
Antonia, S. J.
Perez, B. A.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : S3 - S4
[45] A multicenter phase II study of nivolumab combined with ipilimumab in patients with pediatric solid tumours in adulthood (GETHI021)
Mielgo Rubio, X.
Diaz-Beveritge, R.
Sepulveda Sanchez, J. M.
Pineda, E.
Vaz Salgado, M. A.
Lecumberri, M. J.
Valverde, C.
Lopez Castro, R.
Lopez, C.
Virizuela Echaburu, J. A.
Rodriguez Salas, N.
de las Penas Bataller, R.
Lopez Lopez, R.
Medina Rodriguez, J.
Rodriguez-Antona, C.
Berraondo, P.
Rodriguez-Moreno, J. F.
Hurtado Nuno, A.
Sevillano, E.
Garcia-Donas, J.
ANNALS OF ONCOLOGY, 2020, 31 : S727 - S727
[46] NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Choo, J.
Jeraj, S. Nathan
Chan, G.
Sundar, R.
Yong, W. P.
Lee, M.
Ngoi, N. Y. L.
Wong, A.
Soo, R. A.
Chee, C. E.
Lim, J.
Goh, B-C.
Lee, S. C.
Tan, D. S.
ANNALS OF ONCOLOGY, 2023, 34 : S1498 - S1498
[47] Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study
Andre, Thierry
Tougeron, David
Piessen, Guillaume
de la Fouchardiere, Christelle
Louvet, Christophe
Adenis, Antoine
Jary, Marine
Tournigand, Christophe
Aparicio, Thomas
Desrame, Jerome
Lievre, Astrid
Garcia-Larnicol, Marie-Line
Pudlarz, Thomas
Cohen, Romain
Memmi, Salome
Vernerey, Dewi
Henriques, Julie
Lefevre, Jeremie H.
Svrcek, Magali
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (02) : 255 - +
[48] A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC).
Long, Georgina V.
Atkinson, Victoria
Menzies, Alexander M.
Lo, Serigne
Guminski, Alexander David
Brown, Michael Paul
Gonzalez, Maria Magdalena
Diamante, Katrina
Sandhu, Shahneen Kaur
Scolyer, Richard A.
Emmett, Louise
McArthur, Grant A.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[49] Phase II Study of Nivolumab Plus Ipilimumab with Chemotherapy for Advanced NSCLC with Untreated Brain Metastases: NIke Trial (LOGiK2004)
Tsuchiya-Kawano, Y.
Shiraishi, Y.
Tachihara, M.
Saito, R.
Okamoto, T.
Sugasaki, N.
Nakatomi, K.
Kiyomi, F.
Okamoto, I.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S156 - S156
[50] Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study
Bhatia, Shailender
Topalian, Suzanne L.
Sharfman, William
Meyer, Tim
Steven, Neil
Lao, Christopher D.
Farinas-Madrid, Lorena
Devriese, Lot A.
Moore, Kathleen
Ferris, Robert L.
Honma, Yoshitaka
Elias, Ileana
Srirangam, Anjaiah
Garnett-Benson, Charlie
Lee, Michelle
Nghiem, Paul
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (09)

← 1 2 3 4 5 →